Capecitabine Dosing in Concurrent Chemoradiation for Rectal Cancer
For standard concurrent chemoradiation in rectal cancer, use capecitabine 825 mg/m² twice daily, 5 days per week during radiotherapy. When capecitabine is combined with irinotecan in intensified regimens, reduce the dose to 625 mg/m² twice daily.
Standard Monotherapy Dosing
The most recent and authoritative guidelines from the Chinese Society of Clinical Oncology (CSCO) 2024 clearly specify 825 mg/m² twice daily for 5 days per week when capecitabine is used as the sole chemotherapy agent with radiotherapy 1. This regimen is administered concurrently with 5 weeks of radiotherapy and represents the standard approach for neoadjuvant treatment of locally advanced rectal cancer (cT3-4 or N+).
This dosing is further supported by NCCN guidelines, which recommend capecitabine 825 mg/m² twice daily either 5 or 7 days per week with radiation therapy 2. The FDA label confirms that 825 mg/m² twice daily has been studied in clinical trials for concurrent chemoradiation 3.
Reduced Dosing for Combination Regimens
The dose must be reduced to 625 mg/m² twice daily when capecitabine is combined with irinotecan in intensified concurrent chemoradiotherapy regimens 1. This combination approach is specifically recommended for:
- Patients with UGT1A111 (6/6 type) receiving irinotecan 80 mg/m² weekly
- Patients with UGT1A1128 (6/7 type) receiving irinotecan 65 mg/m² weekly
- Situations requiring intensified treatment to achieve higher pathologic complete response rates, particularly when sphincter preservation is technically challenging but strongly desired
The dose reduction in combination therapy is necessary to manage cumulative toxicity while maintaining efficacy.
Critical Dose Modifications
Renal Impairment
Patients with moderate renal impairment (creatinine clearance 30-50 mL/min) require dose reduction from the standard 825 mg/m² to approximately 75% of the full dose 3. The FDA label demonstrates that moderate renal impairment increases systemic exposure to capecitabine metabolites by 42-85%, necessitating this adjustment. Capecitabine is contraindicated in severe renal impairment (creatinine clearance <30 mL/min).
Age Considerations
While age alone doesn't mandate dose reduction, a 20% increase in age results in a 15% increase in FBAL (metabolite) exposure 3. Elderly patients should be monitored closely for toxicity, particularly if they have concurrent renal impairment.
Food Administration
Capecitabine must be taken within 30 minutes after meals 3. Food reduces peak concentrations by 60% and overall exposure by 35%, which is actually desirable as it reduces toxicity while maintaining efficacy.
Common Pitfalls to Avoid
Do not use 825 mg/m² when combining with irinotecan - this will result in excessive toxicity. The correct dose is 625 mg/m² for combination regimens.
Do not overlook renal function - calculate creatinine clearance before initiating therapy. Even moderate impairment requires dose adjustment.
Do not confuse the rectal cancer dose with other indications - the adjuvant colon cancer dose is 1250 mg/m² twice daily for 14 days every 3 weeks, which is substantially higher and inappropriate for concurrent chemoradiation 3.
Do not administer 7 days per week without careful consideration - while both 5 and 7 days per week are acceptable, the 5-day schedule (Monday-Friday) is more commonly used and may improve tolerability 1.
Treatment Duration and Schedule
Capecitabine is administered throughout the entire radiotherapy course (typically 5-6 weeks), taken twice daily on radiation days only (5 days per week schedule) or continuously (7 days per week schedule). The drug should be taken approximately 12 hours apart, within 30 minutes after meals.